Cargando…

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

BACKGROUND: Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functioning. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camporeale, Angelo, Kudrow, David, Sides, Ryan, Wang, Shufang, Van Dycke, Annelies, Selzler, Katherine J., Stauffer, Virginia L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234796/ https://www.ncbi.nlm.nih.gov/pubmed/30413151 http://dx.doi.org/10.1186/s12883-018-1193-2

Ejemplares similares

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
por: Bangs, Mark E., et al.
Publicado: (2020)

Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
por: Bangs, Mark E., et al.
Publicado: (2020)

Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine
por: Stauffer, Virginia L., et al.
Publicado: (2020)

Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies
por: Stauffer, Virginia L, et al.
Publicado: (2018)

Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
por: Ford, Janet H., et al.
Publicado: (2020)

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
por: Stauffer, Virginia L., et al.
Publicado: (2020)

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
por: Detke, Holland C., et al.
Publicado: (2018)

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
por: Stauffer, Virginia L., et al.
Publicado: (2019)

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Galcanezumab for migraine
Publicado: (2020)

Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
por: Zhou, Jiying, et al.
Publicado: (2023)

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
por: Silberstein, Stephen D., et al.
Publicado: (2019)

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine
por: Ford, Janet H, et al.
Publicado: (2018)

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
por: Silberstein, Stephen D., et al.
Publicado: (2019)

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
por: Kudrow, David, et al.
Publicado: (2021)

Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
por: Martin, Vincent, et al.
Publicado: (2020)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Photophobia and migraine outcome during treatment with galcanezumab
por: Schiano di Cola, Francesca, et al.
Publicado: (2023)

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
por: Reuter, Uwe, et al.
Publicado: (2021)

Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials
por: Jedynak, Jakub, et al.
Publicado: (2021)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
por: Brandes, Jan Lewis, et al.
Publicado: (2019)

A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist
por: Kudrow, David, et al.
Publicado: (2022)

Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
por: Zhao, Xiuyuan, et al.
Publicado: (2020)

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
por: Martinez, James M, et al.
Publicado: (2020)

Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
por: Förderreuther, Stefanie, et al.
Publicado: (2018)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Correction to: Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
por: Zhao, Xiuyuan, et al.
Publicado: (2021)

Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
por: Hu, Bo, et al.
Publicado: (2022)

Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
por: Citrome, Leslie, et al.
Publicado: (2021)

Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
por: Igarashi, Hisaka, et al.
Publicado: (2022)

Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
por: Schoenen, Jean, et al.
Publicado: (2023)

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021)

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
por: Ford, Janet H., et al.
Publicado: (2019)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine
por: Igarashi, Hisaka, et al.
Publicado: (2021)

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
por: di Cola, Francesca Schiano, et al.
Publicado: (2023)

Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
por: Tatsuoka, Yoshihisa, et al.
Publicado: (2021)

Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
por: Rosen, Noah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_asfa85g4atvrtskifvs4tmf2lv